Here are the DEF 14A proxy statements from Cencora, Inc. (COR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow COR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COR filings page.
Cencora is asking shareholders to vote at its virtual 2026 annual meeting on March 5, 2026 to elect 11 directors, approve fiscal 2025 executive pay on an advisory basis, and ratify Ernst & Young LLP as auditor for fiscal 2026. The company reports fiscal 2025 revenue of $321.3 billion and total shareholder return of 40%, and says it returned nearly $900 million through dividends and share repurchases.
Cencora highlights progress on its pharmaceutical‑centric strategy, including acquiring Retina Consultants of America and announcing plans to invest $1.0 billion through 2030 to strengthen its U.S. distribution network. Board refresh and governance are central themes: 10 of 11 nominees are independent, eight have joined in the past five years, and D. Mark Durcan became independent Board Chair on October 1, 2025.
The proxy emphasizes board diversity, succession planning, and extensive shareholder engagement on topics such as the CEO transition to Robert P. Mauch, risk oversight, compensation design, and corporate responsibility. It also details committee structures overseeing capital allocation, executive pay, compliance, risk management, and controlled substances distribution.